news

Oct 10, 2024
Oct 8, 2024
Oct 2, 2024
Linkedin-in

Pipeline & Product

Pipeline & Product

Development Candidate (Indication)

Pre-Clinical

Phase 1

Phase 2

Phase 3

Status/Next Steps

LPCN 1154

Postpartum depression

Finalize validation study protocol based on FDA feedback

LPCN 2201

Major Depressive Disorder (MDD)

Phase 2 POC study

LPCN 2203

Essential Tremor

P1 study completed

LPCN 2101

Epilepsy

Phase 2 POC study

LPCN 1148

Liver Cirrhosis

Phase 2 study completed

LPCN 2401

Obesity Management – adjunct to GLP-1

Seeking regulatory clarity

LPCN 1107

Prevention of Preterm Birth

End of Phase 2 meeting completed

Product

Pre-Clinical

Phase 1

Phase 2/POC

Pivotal

Approved

Status/Next Steps

TLANDO®

TRT

Commercialized by partners (Verity Pharma in the U.S.)

Innovating beyond
boundaries for patients